Akèy › Kansè Poumon ki pa ti selil › North Carolina › Charlotte
Etid klinik pou Kansè Poumon ki pa ti selil nan Charlotte, NC
19 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Charlotte (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Carolinas Medical Center, Charlotte
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Ap rekriteFaz 2
- Levine Cancer Institute, Charlotte
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Atrium Health, Charlotte
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Carolina Oncology Specialists, Charlotte
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Ap rekriteFaz 2
- Atrium Health Levine Cancer, Charlotte
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Carolina Biooncology Institute, Huntersville · 13 mi lwen
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- Levine Cancer Institute, Charlotte
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, LLC, Huntersville · 13 mi lwen
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Ap rekriteFaz 1/2
- Levine Cancer Institute - Charlotte, Charlotte
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
Ap rekriteEtid obsèvasyon
- Atrium Health Levine Cancer, Charlotte
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Clinical Trial Site, Huntersville · 13 mi lwen
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Carolina BioOncology Institute /ID# 232597, Huntersville · 13 mi lwen
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Levine Cancer Institute-SouthPark, Charlotte
- ak 8 plis
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Huntersville · 13 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Charlotte
- Kansè (tout kalite)27 etid
- Kansè nan tete22 etid
- Myelom Miltip21 etid
- Leksemi mieloïd egi16 etid
- Obèsite16 etid
- Sipwa15 etid
- Kansè kolorektal13 etid
- Kansè ovè12 etid
- Ensifizyans kadyak11 etid
- Kansè Metastatik11 etid
- Karsinòm selil skuamèz tèt ak kou10 etid
- BPCO9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.